Dr. Hughes is a member of the Department of Surgical Oncology at the Massachusetts General Hospital and a graduate of Dartmouth College and Dartmouth Medical School.  He trained at the Mercy Hospital of Pittsburgh for general surgery, followed by a fellowship in surgical oncology at the National Cancer Institute.  Dr. Hughes was formerly on the faculty of Tufts University, the University of California, Davis and Brown University.  Dr. Hughes is actively involved in clinical care and research related to the genetics, screening, diagnosis and treatment of breast cancer and is actively involved in the development of Health Information Technology that improves quality while decreasing clinician workload.  He co-authored the HL7, ANSI approved standard for transmitting family health history, and was the Principal Investigator for the Cooperative Group Trial (CALGB 9343) that showed radiation therapy had little benefit in women over age 70 with early breast cancer.  He is the co-creator of the http://www.Ask2Me.Org Clinical Decision Support Tool that calculates risk for patients with cancer susceptibility gene mutations.

Dr. Golshan is the Medical Director of the International Oncology Program for the Dana Farber Cancer Institute and Brigham and Women’s Hospital. He organizes the clinical services for over 2000 patients who come to our institutions each year for care. He has helped lead to a substantial increase in patient volume in the past two years. He is also leading the efforts in building health care relations and centers in China, the Middle East and South America. Dr. Golshan is also the incumbent Dr. Abdul Mohsen and Sultana Al-Tuwaijri Distinguished Chair in Surgical Oncology at the Brigham and Women’s Hospital, the youngest Brigham and Women’s faculty member to be given this distinction. Dr. Golshan is also the Director of the Breast Surgical Oncology Fellowship for the Dana Farber Cancer Institute and Brigham and Women’s Hospital. He also is an Associate Professor of Surgery at Harvard Medical School.   Prior to this Dr. Golshan served as the Director of Breast Surgical Services at the Dana Farber/Brigham and Women’s Cancer Center between 2007-2015.    Dr. Golshan helped build one of the world world’s largest breast surgery programs of 11 full-time breast surgeons operating on nearly 3000 women a year.  He organized the clinical and research efforts of the visiting international breast surgical oncology scholars at the Brigham and Women’s Hospital and Dana Farber Cancer Institute.

Dr. Golshan's research interest is focused primarily on neoadjuvant therapies for breast cancer and the use of novel imaging and operative technologies targeting breast carcinoma. The focus of the preoperative therapy trials is to target treatment for women with cancer and develop genotypic profiles that will in the future lead to individualized tailored therapies for women with breast cancer.  The role of intraoperative and preoperative imaging is also an area of research. In the United States, nearly 40% of women who undergo lumpectomy will need a second operation to achieve clear margins.  We are currently trying to determine if more accurate tumor assessment with breast MRI and mass spectrometry prior to surgery will lead to a decrease in the number of operative procedures required to achieve clear margins.  This is a project fully funded by the Breast Cancer Research Foundation (BCRF).  We are also working on the use of intraoperative imaging assessment with breast MRI in the Advanced Multimodality Image Guided Operative Suite (AMIGO) to determine if we can find residual tumor while the patient is under anesthesia and improve operative outcomes.

I spent nearly 14 years at Brigham and Women’s Faulkner Hospital, which also included a consultancy position at DFCI, providing Breast and Body imging. My expertise in mammography, MRI, ultrasound, and CT allowed me to provide multi-modality patient imaging , and oncology specific second opinions at the Dana Farber Cancer Institute. I joined the Department of Radiology at BIDMC in the Division of Breast Imaging earlier this year where I devote my time to clinical and teaching activities. I enjoy providing radiology training to Harvard Medical Students, Medical and Surgical Residents along with breast Surgical Oncology Fellows. I dedicate my clinical effort to multi-modal breast imaging including mammography, tomosynthesis, ultrasound and breast MRI. Currently my interests are in evolving Breast MRI techniques and contrast enhanced mammography.

Dr. Shelley Hwang is Chief of Breast Surgery and Professor and Vice Chair of Research, Duke University Department of Surgery where she leads translational research activities in early stage and in situ breast cancer.  Dr. Hwang has received local and national recognition for both her clinical expertise and research to improve both cancer and quality of life outcomes in patients affected by breast cancer.  Her research interests include establishing feasibility for less invasive treatments for preinvasive breast cancers, and identifying tumor- and stroma-associated determinants of cancer progression which could be targeted for breast cancer prevention.  She is the PI of a national cooperative group study (CALGB 40903) evaluating the role of preoperative endocrine treatment for low risk DCIS, as well as a national randomized controlled trial of active surveillance for DCIS.  Her laboratory is focused on understanding the evolutionary basis of cancer progression, based on mathematical modeling and cancer genomics.  She also leads a team which seeks to re-engineer electronic data systems to improve delivery of breast cancer care.  She serves as a member of the NCI Breast Cancer Steering Committee, the NCCN Breast Cancer Screening and Diagnosis Panel and Co-Chairs the Locoregional Working Group of the Translational Breast Cancer Research Consortium.  Her research is supported by the NIH, DOD, PCORI, the Susan G. Komen Foundation, the Breast Cancer Research Fund, and The American Cancer Society. 

Dr. Yamina graduated as Medical doctor on 1988 from Ibn Badiss medical school, Constantine, Algeria. She obtained her pathology board in 1994 from Bourgogne university-France under the supervision of professor Eve Justrabo and professor Françoise Piard. She passed with success the French national competitive exam (concour de P.A.C) in 1994. She worked as a consultant in different pathology labs in different hospitals in France: Dijon ,Troyes ...from 1994 till 2003. She moved to UAE where she worked as consultant in Tawam hospital till 2016. Currently she is working as consultant pathologist in Dubai Hospital. Dr. Yamina is keeping in touch with all the new development in histo and cytopathology by attending several national and international courses especially breast and GYN pathology meetings. Her main fields of interest are breast and GYN pathology. She was lead of breast MDT for almost 13 years at Tawam Hospital and still leading the same MDT at Dubai hospital. She loves teaching pathology. She gave many lectures and presented interesting cases in meetings and in the Arab division of AIP .

Dr. Mendez is a breast surgical oncologist at Miami Cancer Institute. She specializes in the treatment of breast cancer and performs all types of breast surgical procedures. Dr. Mendez has contributed to notable breast cancer research and her findings have been widely published. She also has presented abstracts at numerous national and international symposiums and serves on the editorial board of the breast section of the Annals of Surgical Oncology, a commonly used resource. Renowned for her patient care and advocacy, Dr. Mendez is passionate about educating patients and advancing breast cancer awareness and prevention outside the hospital setting, in the community and at national meetings. She was appointed to the governing board of Susan G. Komen,

Massachusetts affiliate. She is a fellow of the American College of Surgeons and an active member of numerous professional societies, including the American Society of Breast Surgeons and the Society of Surgical Oncology.

I am a breast surgeon with more than 25 years of experience in caring for people with breast cancer. I have particular expertise in performing oncoplastic procedures. I combine my oncologic and plastic surgery training to offer the most-effective procedures for my patients, while also maintaining and even enhancing their physical appearance. I care for more than 350 people with breast cancer each year.

Hiram S. Cody III MD, FACS, is a graduate of Dartmouth College and the Columbia University College of Physicians and Surgeons. He completed Surgical Residency at The Roosevelt Hospital in New York, and a Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center, where he is currently Attending Surgeon (Breast Service, Department of Surgery), Member (Memorial Hospital), and Professor of Surgery (Weill Cornell Medical College). His clinical research over the last 25 years has focused on the locoregional management of breast cancer, sentinel lymph node biopsy, and on the interplay between breast imaging, surgery, RT and systemic therapy. He a Past-President of the New York Metropolitan Breast Cancer Group and Past-President of the American Society of Breast Surgeons (2014-2015). He is Editor of the journal Breast Diseases and the multi-author textbook Sentinel Lymph Node Biopsy, serves on many editorial boards, reviews and lectures widely, and is the author of more than 200 peer-reviewed papers, editorials, book chapters and reviews. He and his wife, retired New York Philharmonic violinist Myung-Hi Kim, have three daughters and live on the upper West Side of Manhattan.  

Professor Dixon is a consultant breast surgeon at the Western General Hospital, Edinburgh. He is also Clinical Director of the Breast Cancer Now Research Unit in Edinburgh and holds an Honorary Professorship in Breast Surgery at the University of Edinburgh. Professor Dixon has published over 300 papers, contributed 120 book chapters, and written or edited 25 books.  Professor Dixon has given over 200 invited lectures all around the world. He was the Royal College of Surgeons of Australasia Visiting Fellow in 2000 and 2011. Professor Dixon was the co-chair of the Miami Breast Cancer Conference between 2008 and 2015. In 2013 he was voted the 36th greatest person in Edinburgh of all time and received an OBE from the Queen at Buckingham Palace for his work improving our understanding and improving the management of breast disease. 

Reshma Jagsi, M.D., D.Phil., is Professor and Deputy Chair in the Department of Radiation Oncology and the Center for Bioethics and Social Sciences in Medicine at the University of Michigan. She graduated first in her class from Harvard College and then pursued her medical training at Harvard Medical School. She also served as a fellow in the Center for Ethics at Harvard University and completed her doctorate in Social Policy at Oxford University as a Marshall Scholar. Dr. Jagsi’s medical research focuses on improving the quality of care received by breast cancer patients, both by advancing the ways in which breast cancer is treated with radiation and by advancing the understanding of patient decision-making, cost, and access to appropriate care. Her social scientific research includes research into issues of bioethics arising from cancer care and research regarding faculty development and gender issues, including studies of women's representation in the medical profession. She is the author of over 150 articles in peer-reviewed journals, including the New England Journal of Medicine and JAMA. Her research has been funded by the National Institutes of Health through multiple R01 awards, as well as by numerous philanthropic foundations, including the American Cancer Society, the Robert Wood Johnson Foundation, and the Doris Duke Foundation. She has delivered keynote lectures at numerous institutions, professional societies, and the NIH. She is active in National Cancer Institute cooperative groups for clinical trials, serves in editorial roles for several journals, and has chaired the Research Committee of the Radiation Oncology Institute. She has been elected to the Board of Directors of the American Society of Clinical Oncology (ASCO) and the Steering Committee of the Group on Women in Medicine and Science of the American Association of Medical Colleges (AAMC). She has been honored by election to the American Society of Clinical Investigation.

Dr. Terry Sarantou is a Surgical Oncologist and member of the Academic Faculty of the Division of Surgical Oncology at the Levine Cancer Institute and Department of General Surgery at the Carolinas HealthCare System in Charlotte, NC. He is a board certified general surgeon and Fellow of the American College of Surgeons. He attended medical school at the University of Illinois at Chicago, completed a general surgery residency at the Henry Ford Hospital in Detroit, MI and a surgical oncology fellowship at the John Wayne Cancer Institute in Los Angeles, CA. Dr. Sarantou holds an academic appointment as a Clinical Professor of Surgery at the University of North Carolina at Chapel Hill.

Dr. Sarantou has served as a member on the Commission on Cancer (CoC) for the last sixteen years, holding several positions including North Carolina State Chair for the American College of Surgeons Cancer Liaison Program and currently as a board member on the Cancer Liaison Committee. The Commission on Cancer presented Dr. Sarantou with its Outstanding Achievement Award.

Dr. Sarantou is a member of the Board of Governors of the American College of Surgeons and Chair of the Patient Education Workgroup. He is also a member of the American College of Surgeons Patient Education Committee. Dr. Sarantou was appointed by the Governor of North Carolina to head the committee responsible for writing the North Carolina State Cancer Plan and is a past president of the North Carolina Chapter of the American College of Surgeons.

Dr. Sarantou is Chairman of the Standards and Accreditation Committee of the National Accreditation Program of Breast Centers (NAPBC) and gives lectures for the NAPBC on building a multidisciplinary breast team. He actively surveys and accredits national and international breast programs.

Dr. Sarantou is the Chairman of the American Society of Breast Surgeons Ethics Committee. His committee recently authored a paper in a national journal on the ethics of breast surgery. He is also a past member of the NationalAdjuvant Surgical Breast and Bowel Project Breast Committee.

Dr. Sarantou actively participates in melanoma research and is a member of the Sentinel Node Working Committee for the American College of Surgeons. He trained at the John Wayne Cancer Institute under famed surgical oncologist Dr. Donald Morton, during the time the technique for performing sentinel lymph node biopsies for patients with melanoma and breast cancer was first described

Virgilio Sacchini, MD is Attending Surgeon, in the Breast Service of Memorial Sloan-Kettering Cancer Center in New York and Full Professor of Surgery at the Weill Medical College of Cornell University in New York. He was vice-director of the Breast Department at the European Institute of Oncology in Milan - Italy until September 2000. Dr. Sacchini received his medical degree from the University of Milan Medical School and trained in general surgery at the National Cancer Institute in Milan. In the last 15 years Dr. Sacchini has being involved as co-investigator in several clinical trials in breast cancer. He was Clinical co-ordinator of the Italian Breast Cancer Chemoprevention Study of Tamoxifen. He is participating as clinical investigator in some EORTC (European Organisation for Research and Treatment of Cancer) breast cancer trials. It is in charge of some clinical trials on breast cancer at MSKCC. He is member at large of the Memorial Sloan Kettering Cancer Center Surgical Protocol Review and past member of the Quality Control and Quality Assurance, data and Safety Monitoring Committee, of Memorial Sloan Kettering Cancer Center. Dr. Sacchini has published more than 180 research papers and chapter books.